Clinical Collaboration Announced between Checkmate and BMS

shot by IP News Shots / 7:23 pm on 09 December, 2020

Checkmate Pharmaceuticals Inc. and Bristol Myers Squibb Company have announced a clinical collaboration agreement to assess the combination of a toll-like receptor 9 (TLR9) agonist by Checkmate with a PD-1 blocking antibody, Opdivo by BMS. The agreement of collaboration is aimed at benefiting patients with melanoma or other types of cancers.

Read More at: https://investingnews.com/news/biotech-investing/checkmate-pharmaceuticals-announces-clinical-collaboration-with-bristol-myers-squibb-to-evaluate-cmp-001-in-combination-with-nivolumab/

Industry: Pharmaceuticals | Type of IP: Deals - Other Collaborations